Rocket Pharmaceuticals Income Statement (2014-2026) | RCKT

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
109.77M
Operating items
Research & Development (Quarter)
39.62M33.02M30.79M41.36M43.38M50.04M46.37M51.38M46.84M41.74M45.23M46.34M42.31M37.36M35.94M42.66M34.07M29.35M31.45M29.50M
Selling, General & Administrative (Quarter)
10.03M11.32M11.77M12.85M15.11M19.05M15.82M17.37M18.59M21.54M22.15M27.37M27.11M25.34M28.45M25.02M18.35M14.68M17.06M17.43M
Restructuring Costs (Quarter)
3.47M-0.17M-0.07M
Other Operating Expenses (Quarter)
-0.03M
Operating Expenses (Quarter)
49.65M44.33M42.56M54.21M58.49M69.08M62.19M68.76M65.43M63.28M67.38M73.71M69.42M62.69M64.39M71.15M52.25M43.96M48.51M46.92M
Operating Income (Quarter)
-49.65M-44.33M-42.56M-54.21M-58.49M-69.08M-62.19M-68.76M-65.43M-63.28M-67.38M-73.71M-69.42M-62.69M-64.39M-71.15M-52.25M-43.96M-48.51M-46.92M
EBIT (Quarter)
-49.65M-44.33M-42.56M-54.21M-58.49M-69.08M-62.19M-68.76M-65.43M-63.28M-67.38M-73.71M-69.42M-62.69M-64.39M-71.15M-52.25M-43.96M-48.51M-46.92M
Non-operating items
Interest & Investment Income (Quarter)
0.81M0.85M0.62M0.67M1.35M1.25M1.91M0.85M1.72M0.81M3.03M2.29M1.33M1.62M1.34M0.48M0.71M0.69M0.16M0.35M
Other Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-252.62M-43.95M-126.90M-126.26M-145.59M-68.30M-157.55M-188.38M-190.82M-62.94M-64.82M-71.89M-68.57M-61.55M-63.52M-118.51M-98.92M-43.75M-48.82M131.84M
Profit After Tax (Quarter)
123.21M
Tax Provisions (Quarter)
8.62M
Income from Continuing Operations (Quarter)
123.21M
Consolidated Net Income (Quarter)
123.21M
Income towards Parent Company (Quarter)
123.21M
Net Income towards Common Stockholders (Quarter)
123.21M
Additional items
EPS (Basic) (Quarter)
1.09
EPS (Diluted) (Quarter)
1.08
Shares Outstanding (Quarter)
112.84M
Shares Outstanding (Diluted) (Quarter)
114.51M
EBITDA (Quarter)
-46.92M
Interest Expenses (Quarter)
45.96M
Tax Rate (Quarter)
6.54